Factors Associated with Costs of Hospitalization of Severely Mentally Ill Patients

Martina Curto1-3*, Grace A Masters1, Paolo Girardi1, Ross J Baldessarini1,2 and Franca Centorrino1,2
1Department of Psychiatry, Harvard Medical School, Boston, MA, USA
2Psychopharmacology Lab, McLean Hospital, Belmont, MA, USA
3Department of Psychiatry, Sant’Andrea Medical Center–University of Rome (Sapienza), Italy

Abstract

**Background:** Efforts to contain costs associated with general medical care include particular efforts for psychiatric disorders. Hospitalization represents the largest component of costs for psychiatric care and there is growing interest in balancing clinical needs against limiting costs of inpatient psychiatric care of patients with severe mental illnesses. This study aimed to evaluate clinical factors associated with actual costs of inpatient psychiatric care.

**Method:** We evaluated a cohort of 589 hospitalized psychiatric patients with severe mental illnesses at a nonprofit, university-affiliated psychiatric hospital for factors associated with annualized total costs of inpatient care over a three-year period, using bivariate and multivariate analyses.

**Results:** As expected, days-hospitalized was the major determinant of total costs of hospital care. In addition, several clinical and treatment factors also were associated significantly and independently with costs in multivariate modeling. These included presence of psychosis, electroconvulsive treatment, specialist consultations, use of multiple antipsychotics or of clozapine, and being discharged to a supervised living arrangement, but not sex, age, marital status, employment, or substance abuse.

**Discussion:** As expected, costs of psychiatric hospitalization were dominated by per-diem charges, but also influenced by other, potentially modifiable treatment factors generally associated with more severe psychotic illnesses. The study is based on actual costs rather than on insurer-reimbursements and a large study-sample, though at a single institution. Specific factors identified encourage focusing on patient characteristics associated with greater costs and redoubled efforts to apply and improve alternative, cost-effective interventions such as partial-hospital and intensive outpatient treatment.

Keywords: Antipsychotics; Costs; Factors; Hospitalization; Major mental illness; Psychosis; Psychiatric care

Introduction

Major mental illnesses are prevalent disorders that contribute to a substantial proportion of overall illness burdens. Excluding dementias, they occur at a combined lifetime prevalence of nearly 5% for psychotic and bipolar disorders and approximately 10% for major depressive disorder [1-3]. As largely chronic or recurrent illnesses, they carry high risks of disability and early mortality, in addition to representing extraordinary direct (care) and indirect (disability) costs to society [4-11]. Such disorders particularly during acute dysfunction, dangerousness, and with commonly co-occurring general medical illness represent the most frequent reason for hospitalization in psychiatric units of general hospitals as well as specialized institutions [2,3,12-14]. Moreover, the costs would be far larger if not for the major diversion of the severely mentally ill to the criminal justice system, particularly in the US [15-18].

Along with efforts to contain costs associated with general medical care, there have been particular efforts to limit costs of treating patients with psychiatric disorders [19,20]. Annual costs of care for mentally ill persons in the US now exceed $200-billion. This is the third highest category of healthcare costs in the nation, tied with cancer, and representing a substantial proportion of total national health care expenditures, now approaching $4-trillion per year [19,21-23]. The largest component of the costs for psychiatric care is hospitalization-representing between a quarter and one-third of total costs; the remainder is associated with partial-hospital and ambulatory care, prescription drugs, and administrative costs [5]. As a leading contributor to the costs of care, hospitalization is a target of intense scrutiny among insurers, administrators, and others seeking to rein in costs of mental health services, while balancing the obligation to meet clinical needs [19,20,24].

Facilitating efforts to limit costs, modern clinical psychopharmacology has helped to provide a relatively efficient and cost-effective component of treatment. The rise of pharmacotherapy has been associated with less frequent and shorter hospitalizations, brief outpatient visits and less emphasis on lengthy psychotherapies, especially for patients with relatively mild or moderate illnesses [25,26]. Nevertheless, psychiatric hospitalization, especially of the severely mentally ill, has been unavoidable and the costs of hospitalization [and incarceration] remain a leading financial strain to individuals, third-party payers, and society [5,12,27-29]. Efforts to manage costs associated with psychiatric illness include increasingly strenuous requirements by insurers tendency to limit hospital admissions and days per admission.

*Corresponding author: Martina Curto, NeSMOS, Sant’Andrea Hospital, Via di Grottarossa 1035-1039, Rome 00189, Italy, Tel: + 39 063 3775951; E-mail: martina.curto@gmail.com

Received October 23, 2015; Accepted January 30, 2016; Published February 07, 2016

Citation: Curto M, Masters GA, Girardi P, Baldessarini RJ, Centorrino F (2016) Factors Associated with Costs of Hospitalization of Severely Mentally Ill Patients. Bipolar Disord 2: 103. doi:10.4172/2472-1077.1000103

Copyright: © 2016 Curto M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Factors associated with hospitalization costs

We compared estimated, annualized total inpatient treatment costs per person for each subject over the three years sampled. A total of 21 factors, individually, were associated with greater costs per person (18–22%) and entered stepwise. Averages are presented as means ± standard deviation (SD) or with 95% confidence interval (CI); results of linear regression modeling were reported as slope functions (β) with CI. Statistical significance required two-tailed p<0.05, with Bonferroni adjustment for testing of multiple individual factors.

Results

Characteristics of subjects

Study subjects (N=589) averaged 35.7 ± 13.0 [18-68] years of age; 59.6% were men, and 81.8% were Caucasian. Overall duration of illness from onset averaged 12.4 ± 9.68 years, including the three years of observation (Table 1). Primary psychiatric diagnoses (DSM-5 criteria) ranked: bipolar disorder (36.0%), schizoaffective disorder (18.2%), major depressive disorder (14.4%), schizophrenia (13.1%), other psychotic disorders (12.6%) and other disorders (5.77%). Initial index hospitalizations were first-lifetime admissions for 17.3% of subjects and 84.3% of these involved psychotic disorders; 36.3% of subjects were hospitalized more than once over the three-year period sampled, at an average of 0.51 ± 0.29 hospitalizations/person-year, lasting on average 13.3 ± 12.3 days per admission. Salient characteristics are summarized in Table 1.

Factors associated with hospitalization costs

We compared estimated, annualized total inpatient treatment costs per person for each subject over the three years sampled. A total of 21 factors, individually, were associated with greater costs per person (18% met the Bonferroni-adjusted significance criterion of p ≤ 0.002, and 16 of these were not directly related to days/year in hospital; Table 2). Comparisons of matched pairs of mean costs/person/year for each factor were contrasted by the ratio of costs with the factor present/absent. In addition, we computed standardized differences (Cohen's d-statistic for each cost-pair [not shown]). These ranged from 2.06 for cases involving hospitalization for ≥ 14 days, to 0.26 for the presence of a lifetime suicidal act. Since the rate-ratio measures shown correlated very closely with values of d-statistic (r=0.998), we report the rate-ratio data to indicate the magnitude of cost differences for each covariate (Table 2).
### Table 1: Characteristics of study subjects.

| Characteristic                                           | Measure |
|----------------------------------------------------------|---------|
| Cases (n, %)                                             | 589 (100) |
| Men                                                      | 351 (59.6) |
| Women                                                    | 238 (40.4) |
| Social factors                                           |         |
| GAF at initial admission                                 | 28.5 ± 5.73 |
| Married (%)                                              | 14.9 |
| Employed (%)                                             | 36.7 |
| Pre-admission supervised living (%)                      | 13.6 |
| Discharged to supervised living (%)                      | 19.5 |
| Diagnosis (%)                                            |         |
| Bipolar disorder                                         | 36.0 |
| Schizoaffective disorder                                 | 18.2 |
| Major depressive disorder                                | 14.4 |
| Schizophrenia                                            | 13.1 |
| Other psychoses                                          | 12.6 |
| Other disorders                                          | 5.77 |
| Years ill *                                              | 12.4 ± 9.68 |
| General medical illnesses                                |         |
| Subjects affected (n, %)                                 | 345 (58.6) |
| Diagnoses/person                                         | 1.71 ± 2.07 |
| Clinical factors (≤ 6 months; %)                         |         |
| Substance abuse                                          | 58.6 |
| Suicidal ideation or act                                 | 60.1 |
| Treatments (at first discharge)                          |         |
| ≥ 2 psychotropics/person                                 | 69.4 |
| Psychotropics/person                                     | 2.08 ± 1.04 |
| Nonpsychotropic medicines/person                         | 2.57 ± 2.54 |
| ≥ 2 antipsychotics (%)                                   | 16.3 |
| Clozapine (%)                                            | 9.85 |
| ECT                                                      | 7.13 |
| Psychiatric hospitalization                              |         |
| Admissions/year                                          | 0.51 ± 0.29 |
| Days hospitalized/year                                   | 6.85 ± 4.97 |
| Days/admission                                           | 13.3 ± 12.3 |

[7] Includes the 3 years of observation

### Table 2: Factors associated with total annualized costs of psychiatric inpatient treatment.

| Factor                                               | Present | Absent | Ratio | t-score | p-value |
|-------------------------------------------------------|---------|--------|-------|---------|---------|
| >14 Hospital days total                               | 14.4 ± 8.27 | 4.33 ± 1.49 | 3.33 | 20.4 | <0.0001 |
| ≥2 Hospitalizations/3 years                          | 15.3 ± 8.80 | 6.25 ± 4.83 | 2.45 | 16.1 | <0.0001 |
| Clozapine given                                       | 16.2 ± 11.3 | 8.77 ± 7.00 | 1.85 | 7.12 | <0.0001 |
| ECT given                                             | 17.0 ± 10.4 | 8.92 ± 7.31 | 1.91 | 6.67 | <0.0001 |
| ≥2 Consultations per admission                        | 11.8 ± 9.29 | 8.18 ± 6.55 | 1.44 | 5.53 | <0.0001 |
| ≥2 Non-psychotropic medicines                        | 10.9 ± 8.78 | 7.43 ± 5.65 | 1.47 | 5.41 | <0.0001 |
| Initial hospitalization, first-lifetime               | 6.25 ± 4.89 | 10.2 ± 8.18 | 0.61 | 4.68 | <0.0001 |
| Non-independent living post-hospitalization           | 12.2 ± 10.1 | 8.83 ± 7.06 | 1.38 | 4.24 | <0.0001 |
| Schizophrenia/schizoaffective diagnosis vs. major affective disorder diagnosis | 11.1 ± 9.16 | 8.36 ± 6.41 | 1.33 | 4.18 | <0.0001 |
| Unemployed                                            | 10.5 ± 8.60 | 7.79 ± 5.85 | 1.35 | 4.04 | <0.0001 |
| ≥10 years total                                       | 10.7 ± 8.69 | 8.18 ± 6.29 | 1.31 | 3.97 | <0.0001 |
| ≥2 Medical diagnoses                                  | 10.9 ± 8.91 | 8.47 ± 6.82 | 1.29 | 3.78 | 0.0002 |
| ≥2 Antipsychotic drugs/admission                      | 12.6 ± 9.11 | 9.04 ± 7.55 | 1.39 | 3.74 | 0.0002 |
| Age initially ≥ 40 years                               | 11.0 ± 9.21 | 8.54 ± 6.66 | 1.29 | 3.69 | 0.0002 |
| >2 Psychotropic drugs/admission                       | 11.2 ± 8.71 | 8.75 ± 7.32 | 1.28 | 3.47 | 0.0006 |
| Psychotic in hospital                                 | 10.1 ± 8.26 | 7.81 ± 6.36 | 1.39 | 3.22 | 0.001 |
| Suicidal act ever                                     | 10.7 ± 9.56 | 8.62 ± 6.24 | 1.24 | 3.18 | 0.002 |
| BMI ≥ 25 kg/m²                                         | 10.3 ± 8.34 | 8.23 ± 6.94 | 1.25 | 3.05 | 0.002 |

Data are mean ± SD of annualized costs for psychiatric hospital care over 3 years in N=589 patient-subjects [94.2% with psychotic or major affective disorder diagnoses]. The overall mean cost/year was 9496 [CI: 8861–10,132 USD]. Factors [n=18] are ranked in descending order of significance, based on a Bonferroni adjusted criterion of \( p \leq 0.022 \) [0.05/21] as significant; 16 were not directly related to hospitalization itself. Factors not associated with cost of hospital treatment included: [a] sex, [b] marital status, [c] smoking or substance abuse, [d] suicidal ideation within 6 months, [e] inpatient brain MRI or EEG studies, [f] considered poorly adherent to outpatient treatment, [g] living non-independently prior to hospitalization, and [h] GAF <30 at initial admission.

### Multivariate modeling

We employed multivariate linear regression modeling to identify factors preliminarily found to be associated with hospital-based costs-of-care (see Table 2), examining each for significant and independent association with costs. The number of days hospitalized/year accounted for the highest proportion of total hospitalization costs (94.9% [CI: 94.0–94.8]). Based on multivariate linear regression modeling, with total costs of inpatient care per person averaged $9500 (CI: 8860–10,100) USD/year. As expected, factors most associated with greater costs were more hospitalizations and more days hospitalized accounting for more than 90% of total costs. Nevertheless, other clinical and treatment factors also were significantly associated with higher total costs. Notably, these included a diagnosis of non-affective psychotic disorder, treatment with clozapine, use of multiple psychotropic drugs or multiple antipsychotics per person, two or more general medical illnesses and multiple non-psychiatric medicines, and receiving electroconvulsive treatment (ECT). In addition, unemployment, age initially ≥ 40 years, non-Caucasian race, and discharge to a supervised living situation such as a group home (but not living in such a setting prior to admission) were associated preliminarily with higher costs. Having multiple medical diagnoses, receiving consultations with medical or psychiatric specialists, and a relatively large number of laboratory tests (excluding EEG and MRI procedures) also were related to higher costs. Diagnosis of schizophrenia or schizoaffective disorder was associated with greater costs than diagnoses of bipolar disorder or major depressive disorder (by 36%) (Table 3), as was lifetime suicidal behavior (by 24%). However, an Axis II diagnosis and lack of psychiatric hospitalization prior to the index admission were associated with less cost. Marital status, sex, and substance abuse were not significantly associated with hospitalization costs. Effects of selected factors on costs of hospital-care are summarized in Figure 1.
hospitализаций/year retained as an independent variable, six other
significantly associated factors ranked [by β with CI]: [a] treatment with
ECT (β = 16.0 (10.3–21.8)), [b] treatment with clozapine (12.5 (7.32–
17.8)), [c] discharge to a supervised living situation (7.02 (3.22–10.8)),
[d] diagnosis of a non-affective or schizophrenic psychotic disorder (3.86
(0.70–7.03)), [e] more specialist consultations in hospital (3.64
(2.16–5.11)), and [f] more antipsychotics/person in hospital (2.73
(1.08–4.38); not shown). As expected, factors associated with overall
costs of inpatient care were also correlated with days hospitalized per year.

Discussion

The present findings are based on assessments of 589 patients
diagnosed with a DSM-5 psychotic or major affective disorder, treated
and followed at a university-affiliated psychiatric hospital. They confirm
that many clinical and administrative factors are associated with,
or contribute to overall actual costs of psychiatric inpatient care. As
expected, the dominant driver of costs (>90%) were per diem charges
for hospitalization. In addition, however, 16 factors, not directly related
to days hospitalized, also were significantly associated with higher total
costs per person-year (Table 2). Notably this included sex, marital status,
substance abuse, use of relatively expensive diagnostic tests, suspected
poor adherence to previous treatment, and living non-independently.
Most factors associated with costs appear to reflect relatively severe or
complex illnesses, including treatment with clozapine, multiple
antipsychotics, or ECT, specialist-consultations in hospital, having
multiple, co-occurring general medical conditions, and receiving
multiple non-psychotropic medicines. Diagnostically, patients with a
primary, non-affective or schizoaffective psychotic disorder (Table 3)
and those with psychotic features in any disorder, as well as suicidal
behavior at any time were substantially more costly than subjects lacking
such features. More years of lifetime illness, being older, unemployed,
or requiring a supervised living situation after discharge also were
associated with higher costs of care (Table 2, Figure 1). Notably, too,
lower costs were associated with the index hospitalization as a first-
lifetime experience; this factor, too, probably reflects differences
between subjects with recent, relatively acute illnesses and those with
prolonged or recurrent illnesses. This interpretation also accords with
striking differences in costs between subjects with chronic, psychotic
disorders versus mood disorders (Table 3).

In linear multivariate modeling, six factors remained associated
independently and significantly with higher costs of hospital care,
even with number of hospitalizations/year retained as an independent
covariate (Table 4). These included diagnosis of a primary psychotic
disorder (schizophrenia or schizoaffective disorder), more specialist
consultations, treatment with ECT, clozapine, or multiple antipsychotic
drugs, and being discharged to a supervised aftercare facility.
Unsurprisingly, the same factors also correlated with days/year
hospitalized.

Again, we propose that most of the identified factors reflect more
severe and prolonged illnesses that were relatively difficult to treat and
required more time in hospital. It is notable, for example, that use of
clozapine has been associated with savings in treatment costs in other
circumstances notably, in comparisons of similarly severely ill subjects
treated with this unusually effective drug versus others [56,57]. Here,
however, use of clozapine evidently signals unusually severe and
otherwise inadequately treatment-responsive illness.

Although this study considered actual costs rather than insurance-
reimbursements, the observed costs at the study site were close to
reported hospitalization costs of similarly diagnosed (mainly psychotic
and bipolar disorder) subjects in other comparable settings [40,44]. The
estimated total cost of hospital treatment was approximately $714/day
of hospitalization over three years, with an average of 13 days/admission
at the study site. These findings compare well with recent estimates
of $793/day in hospital for comparably diagnosed subjects in other
comparable settings [40,44]. The estimated total cost of hospital treatment was approximately $714/day
of hospitalization over three years, with an average of 13 days/admission
at the study site. These findings compare well with recent estimates
of $793/day in hospital for comparably diagnosed subjects in other
comparable settings [40,44].
were similar to those estimated on the basis of insurers’ reimbursement rates used in other studies of the costs of clinical care [5,20,43]. It is also interesting to compare the costs of psychiatric hospitalization to those for common general medical disorders. For example, recent cost-estimates of hospitalization for stroke have averaged 21.8 (CI: 4.70–39.0), and for a heart attack or comparable cardiac illness, 27.3 (8.75–35.8) thousands of US dollars, or 2.3–2.9-times more than the average cost of psychiatric hospitalization at the present study site, 9.50 (8.86–10.1) [58-60].

Many of the cost-associated factors identified appear to be related to longer-lasting or more severe illness, apparent treatment-resistance, and consequent disability. It is plausible that improved long-term treatments and clinical management that can limit acute symptoms as well as long-term morbidity and disability and provide supportive protection can reduce costs of psychiatric hospitalization overall [36,43]. Such a conclusion is hardly surprising, and efforts to improve the care of the severely and chronically mentally ill are a major focus of contemporary psychiatric research and practice. Nevertheless, such efforts should have high priority, with specific attention to both anticipated cost-savings and cost-shifting. Less costly alternatives include practicable and well-tested options, such as partial-hospital, day-treatment, group homes, intensive outpatient care, and active community management programs. However, such programs vary widely in their accessibility and support by third-party payers, despite proven to be effective and less costly than hospitalization [36,37,43,61-64].

A major limitation of the present study is that the study sample, though large, only considered severe mental illnesses requiring inpatient care. Additionally, as the sample is from a single institution, it may not fully adequately represent other types of hospitals in other locations, although the costs encountered and lengths of hospitalization were similar to those reported in other recent studies, as noted [40,44]. A notable feature of the present analyses is their basis on actual costs rather than on insurer reimbursement rates, as have been used in other studies of costs of psychiatric treatment [5,20].

Conclusion

Not surprisingly, the present findings indicate that measures consistent with severe, chronic, and treatment-resistant psychotic illnesses were significantly associated with greater costs of inpatient psychiatric treatment, controlling for effects of hospitalization frequency. Specific factors identified encourage focusing on patient characteristics associated with greater costs and redoubled efforts to apply and improve cost-effective alternatives to psychiatric hospitalization.

Acknowledgement

Supported, in part, by a Psychiatric Research Fellowship from the Sapienza Foundation of the University of Rome and Sant’Andrea Medical Center (to MC), a Psychiatric Research fellowship from the Sapienza Foundation of the University of Rome and Sant’Andrea Medical Center (to MC), a World Health Organization (WHO) (2008) Global Burden of Disease: 2004 Update. WHO Press, Geneva, Switzerland.

Kessler RC, Aguilar-Gaxiola S, Alonso J, Chatterji S, Lee S, et al. (2009) The global burden of mental disorders: an update from the WHO World Mental Health (WMH) surveys. Epidemiol Psychiatr Soc 18: 23-33.

Ekmans M, Granstrom O, Omerov S, Jacob J, Landen M (2013) The societal cost of schizophrenia in Sweden. J Ment Health Policy Econ 16: 13-25.

Parker G, McGraw S, Hadzi-Pavlovic D, Fletcher K (2013) Costs of the principal mood disorders: study of comparative direct and indirect costs incurred by those with bipolar I, bipolar II and unipolar disorders. J Affect Disord 149: 46-55.

Bock JO, Luppia M, Brettschneider C, Riedel-Heller S, Bickel H, et al. (2014) Impact of depression on health care utilization and costs among multimorbid patients—from the MultiCare Cohort Study. PLoS One 9: e91973.

Ascher-Svanum H, Zhu B, Faries DE, Salkever D, Slade EP, et al. (2010) The cost of relapse and the predictors of relapse in the treatment of schizophrenia. BMC Psychiatry 10: 2.

Blader JC (2011) Acute inpatient care for psychiatric disorders in the United States, 1996 through 2007. Arch Gen Psychiatry 68: 1276-1283.

Fok ML, Stewart R, Hayes RD, Moran P (2014) Impact of co-morbid personality disorder on use of psychiatric services and involuntary hospitalization in people with severe mental illness. Soc Psychiatry Psychiatr Epidemiol 49: 1631-1640.

Domino ME, Norton EC, Morrissey JP, Thakur N (2004) Cost shifting to jails after a change to managed mental health care. Health Serv Res 39: 1379-1401.

Department of Justice (DOJ) (2006) Mental Health Problems of Prison and Jail Inmates (Publication No. NCC-218300). Bureau of Justice Statistics, US Department of Justice, Washington, DC.

Harcourt BE (2007) The mentally ill, behind bars. New York Times.

Kuehn BM (2014) Criminal justice becomes front line for mental health care. JAMA 311: 1953-1954.

Levit KR, Kassed CA, Coffey RM, Mark TL, McGusik DR, et al. (2008) Projections of National Expenditures for Mental Health Services and Substance Abuse Treatment, 2004–2014. Publication No. SMA 08-4326. US Substance Abuse and Mental Health Services Administration [SAMHSA], Rockville, MD.

Starr P (2012) Remedy and Reaction: The Peculiar American Struggle Over Health Care Reform. Yale J Biol Med 85: 159-160.

Insel TR (2008) Assessing the economic costs of serious mental illness. Am J Psychiatry 165: 663-665.

Insel TR (2011) The economics of mental health care reform.

Munro D (2014) Annual US healthcare spending hits $3.3 trillion. Forbes Magazine.

Masters GA, Baldessarini RJ, Öngür D, Centorrino F (2014) Factors associated with length of psychiatric hospitalization. Compr Psychiatry 55: 681-687.

Baldessarini, Ross J (2013) Chemotherapy in Psychiatry, third edition. New York: Springer Press.

Baldessarini RJ (2014) The impact of psychopharmacology on contemporary psychiatry. Can J Psychiatry 59: 401-405.

Barnett PG, Scott JY, Krystal JH, Rosenheck RA; CSP 555 Research Group (2012) Cost and cost-effectiveness in a randomized trial of long-acting risperidone for schizophrenia. J Clin Psychiatry 73: 696-702.
Citation: Curto M, Masters GA, Girardi P, Baldessarini RJ, Centorrino F (2016) Factors Associated with Costs of Hospitalization of Severely Mentally Ill Patients. Bipolar Disord 2: 103. doi:10.4172/2472-1077.1000103